7 Surprising Ways GLP-1s Are Changing Health in Alaska Beyond the Scale

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, adjusting, or stopping any medication, including GLP-1 receptor agonists.

Most Alaskans know GLP-1 medications as the weight loss drugs. But scientists are discovering that these medications, originally developed for type 2 diabetes, have a remarkably wide impact on human health that goes far beyond how much you weigh.

This matters especially in Alaska. According to the Alaska Department of Health's Chronic Disease Facts report, three out of four Alaska adults have underlying health conditions that increase the risk of serious illness, including cardiovascular disease, kidney disease, type 2 diabetes, and obesity. Heart disease and cancer are the top two causes of death in the state. GLP-1 medications are now showing evidence-backed benefits across nearly all of these conditions.

A landmark review published in Cell Reports Medicine (2025) found that GLP-1 medicines improve outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea conditions, with some benefits operating through anti-inflammatory and metabolic pathways that are "partly independent of the degree of weight loss achieved."

Here are 7 areas where GLP-1 research is producing genuinely compelling results in 2025, and why they matter for Alaskans specifically.

Benefit 1 Heart Health: Fewer Heart Attacks and Strokes

This is one of the most thoroughly documented benefits. The SELECT trial (N Engl J Med, 2023) enrolled 17,604 overweight and obese adults with pre-existing cardiovascular disease but without diabetes. Those taking semaglutide 2.4 mg weekly had a 20% lower risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, compared to placebo over a mean follow-up of 39.8 months.

For Alaskans, where heart disease is the leading cause of death and access to cardiology specialists is often limited to Anchorage and a handful of larger cities, the cardiovascular protection offered by GLP-1s is particularly relevant. The American College of Cardiology now recommends GLP-1 medications as a tool to reduce cardiovascular disease risk in eligible patients.

Benefit 2 Kidney Protection: Slowing Disease Progression

The FLOW trial (N Engl J Med, 2024) was a landmark kidney outcomes study enrolling 3,533 adults with type 2 diabetes and chronic kidney disease. The trial was stopped early due to the clear efficacy of semaglutide. Key findings:

• 24% reduction in the risk of major kidney disease events
• 18% reduction in major cardiovascular events
• 20% reduction in all-cause mortality

Kidney disease affects a significant portion of Alaskans, particularly Alaska Native communities, where diabetes-related kidney disease has been documented at elevated rates. The FDA's January 2025 expansion of semaglutide's approved uses to include reducing kidney disease progression is directly relevant to high-risk patients across the state.

Benefit 3 Liver Disease: Clearing Fatty Liver (MASH)

On August 15, 2025, the FDA granted accelerated approval to Wegovy (semaglutide) for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. This makes semaglutide the first GLP-1 receptor agonist approved for MASH.

The approval was based on the phase 3 ESSENCE trial. At the 72-week interim analysis, 63% of participants taking semaglutide achieved resolution of MASH with no worsening of liver scarring, compared to 34% in the placebo group. MASH affects approximately 1 in 20 American adults and is closely linked to obesity and type 2 diabetes, conditions with elevated rates in Alaska. For many Alaskans, a GLP-1 prescription could now be addressing weight, cardiovascular disease, kidney health, and liver disease simultaneously.

Benefit 4 Sleep Apnea: Meaningful Symptom Reduction

Obstructive sleep apnea is strongly associated with obesity and is highly prevalent in Alaska, where sedentary winter lifestyles and high obesity rates create significant risk. Clinical trials have shown that GLP-1 medications can meaningfully reduce the severity of sleep apnea, both through weight loss and through potential direct effects on upper airway muscle tone and central nervous system signaling, according to the Cell Reports Medicine review (2025). For Alaskans managing sleep apnea alongside obesity, GLP-1s may offer meaningful relief.

Benefit 5 Brain Health: A Possible Role in Alzheimer's Prevention

This is one of the most exciting frontiers in GLP-1 research. GLP-1 receptors are found throughout the brain, and early data suggest these medications may modulate neuroinflammation, a key driver of cognitive decline.

As noted in the PMC narrative review of expanding GLP-1 applications (2025), people with type 2 diabetes on GLP-1 medications show a lower risk of all-cause dementia, including Alzheimer's disease. The ongoing EVOKE clinical trials are testing whether oral semaglutide can modify the course of early symptomatic Alzheimer's disease, with results expected in 2026.

Benefit 6 Joint Pain: Reducing Osteoarthritis Symptoms

Emerging research suggests that GLP-1 medications may reduce pain and improve mobility in people with osteoarthritis, both through mechanical relief on joints as weight decreases and through anti-inflammatory mechanisms that appear at least partly independent of weight loss. For Alaskans who rely on physical capability for work, subsistence activities, or outdoor recreation, this is a potentially meaningful secondary benefit, as highlighted in the Cell Reports Medicine 2025 review.

Benefit 7 Addiction and Cravings: Quieting the Reward System

GLP-1 receptors are found in the brain's reward and motivation centers, including the central amygdala. Early research in animals and observational studies in humans suggest that GLP-1 medications may reduce cravings for alcohol, nicotine, and other addictive substances. Alaska has well-documented struggles with alcohol use disorders, particularly in rural and Alaska Native communities. A 2025 narrative review of GLP-1 applications found early promise for GLP-1 receptor agonists in reducing alcohol and substance cravings. Larger clinical trials are currently underway to confirm these findings.

The Bigger Picture for Alaska

GLP-1 medications are evolving from weight loss drugs into something much broader: systemic health tools that affect nearly every major organ system. For a state where chronic disease burden is high, specialist access is limited, and the cost of poor metabolic health is felt across families and communities, this class of medications carries significant promise.

Not every benefit is confirmed at every dose or for every patient, and the science is still developing. But if you or someone you care for is living with obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, or fatty liver disease anywhere in Alaska, it is worth a serious conversation with a qualified provider about whether a GLP-1 medication belongs in your health plan.